📊 DNLI Key Takeaways
Is Denali Therapeutics Inc. (DNLI) a Good Investment?
Pre-revenue biotech company burning $131M+ annually with no revenue generation or clear path to profitability. Financial viability entirely dependent on successful drug development outcomes. Strong cash position provides ~3 year runway, but high burn rate and development risk dominate fundamental analysis.
Denali Therapeutics remains a pre-revenue biotech with substantial operating and free cash flow losses, and profitability trends are deteriorating as net losses widened year over year. While the balance sheet is currently strong with high liquidity, no long-term debt, and over $1.0B in equity, the core fundamental question is whether the company can convert R&D spending into durable commercial or partnership revenue before cash burn materially weakens financial flexibility.
Denali Therapeutics Inc. Key Strengths (DNLI)
- Substantial cash reserves of $387.6M providing significant operational runway
- Zero long-term debt with conservative capital structure eliminating refinancing risk
- Strong liquidity position with 9.28x current ratio and minimal near-term obligations
- Very strong liquidity profile with 9.16x current and quick ratios
- Debt-free capital structure reduces financial distress risk
- Large equity base and modest liabilities provide balance sheet support
DNLI Stock Risks: Denali Therapeutics Inc. Investment Risks
- Negative operating cash flow of -$131.2M indicating unsustainable burn rate requiring successful pipeline execution
- Zero revenue with no demonstrated commercial viability or near-term revenue inflection
- Complete dependence on R&D success and clinical trial outcomes with inherent binary risk structure
- Zero revenue means the business is still fully dependent on external funding or existing cash reserves
- Operating cash burn is very high, with negative free cash flow of roughly $422M
- Net losses worsened year over year, indicating weak near-term profitability trajectory
Key Metrics to Watch
- Quarterly operating cash burn rate and remaining cash runway duration
- Pipeline advancement milestones and clinical trial enrollment/success rates
- Capital raising requirements and ability to secure future financing
- Quarterly cash burn relative to cash and equivalents
- Any sustained revenue generation from product commercialization or collaboration milestones
Denali Therapeutics Inc. (DNLI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.28x current ratio provides a solid financial cushion.
DNLI Profit Margin, ROE & Profitability Analysis
DNLI vs Healthcare Sector: How Denali Therapeutics Inc. Compares
How Denali Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Denali Therapeutics Inc. Stock Overvalued? DNLI Valuation Analysis 2026
Based on fundamental analysis, Denali Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Denali Therapeutics Inc. Balance Sheet: DNLI Debt, Cash & Liquidity
DNLI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Denali Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 1% decline. The most recent EPS of $-1.06 indicates the company is currently unprofitable.
DNLI Revenue Growth, EPS Growth & YoY Performance
DNLI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$25.8M | $-0.19 |
| Q2 2024 | N/A | $73.6M | $0.52 |
| Q1 2024 | N/A | -$101.8M | $-0.68 |
| Q3 2023 | $184.0K | -$25.8M | $-0.19 |
| Q2 2023 | $52.5M | -$58.8M | $-0.48 |
| Q1 2023 | $35.1M | -$65.2M | $-0.53 |
| Q3 2022 | $184.0K | -$84.6M | $-0.69 |
| Q2 2022 | $22.9M | -$58.8M | $-0.48 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Denali Therapeutics Inc. Dividends, Buybacks & Capital Allocation
DNLI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Denali Therapeutics Inc. (CIK: 0001714899)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jun 5, 2026 | 4 | xslF345X06/wk-form4_1780692384.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/wk-form4_1780692356.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/wk-form4_1780692340.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/wk-form4_1780692324.xml | View → |
| Jun 5, 2026 | 4 | xslF345X06/wk-form4_1780692307.xml | View → |
❓ Frequently Asked Questions about DNLI
What is the AI rating for DNLI?
Denali Therapeutics Inc. (DNLI) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 74% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DNLI's key strengths?
Claude: Substantial cash reserves of $387.6M providing significant operational runway. Zero long-term debt with conservative capital structure eliminating refinancing risk. ChatGPT: Very strong liquidity profile with 9.16x current and quick ratios. Debt-free capital structure reduces financial distress risk.
What are the risks of investing in DNLI?
Claude: Negative operating cash flow of -$131.2M indicating unsustainable burn rate requiring successful pipeline execution. Zero revenue with no demonstrated commercial viability or near-term revenue inflection. ChatGPT: Zero revenue means the business is still fully dependent on external funding or existing cash reserves. Operating cash burn is very high, with negative free cash flow of roughly $422M.
What is DNLI's revenue and growth?
Denali Therapeutics Inc. reported revenue of $0.0.
Does DNLI pay dividends?
Denali Therapeutics Inc. does not currently pay dividends.
Where can I find DNLI SEC filings?
Official SEC filings for Denali Therapeutics Inc. (CIK: 0001714899) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DNLI's EPS?
Denali Therapeutics Inc. has a diluted EPS of $-0.69.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is DNLI's fundamental grade?
Based on our AI fundamental analysis in June 2026, Denali Therapeutics Inc. has a C grade with 74% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is DNLI stock overvalued or undervalued?
Valuation metrics for DNLI: ROE of -13.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is DNLI's AI grade for 2026?
Our dual AI analysis gives Denali Therapeutics Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DNLI's free cash flow?
Denali Therapeutics Inc.'s operating cash flow is $-131.2M, with capital expenditures of $2.5M.
How does DNLI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -13.9% (avg: 15%), current ratio 9.28 (avg: 2).